CION Ameerpet
Diagnosis · Reviewed by CION Oncologists · NABH Accredited
Molecular Classification — POLE, MMR and p53 Explained
For decades endometrial cancers were sorted by how the cells looked under a microscope. That worked reasonably well and it missed something important: two tumours that look identical can behave completely differently. Molecular classification sorts them by what is actually driving them, into four groups — POLE-ultramutated, mismatch repair deficient, p53-abnormal, and no specific molecular profile. It is now built into FIGO 2023 staging, so it is not an optional extra. The part most explanations leave out is that this can mean less treatment as readily as more. A POLE-mutated tumour that looks aggressive down the microscope frequently is not, and knowing that spares women treatment they would otherwise have had.
- Four groups, not one spectrum — each with a distinct outlook
- Now part of staging itself — FIGO 2023 incorporates it
- POLE often means less treatment — the part usually left unsaid
- MMR testing also finds Lynch syndrome — with implications for your family
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The Four Molecular Groups
What each means, how it is identified, and what it tends to change about treatment.
| Group | What it means |
|---|---|
| POLE-ultramutated | A fault in the proofreading part of the POLE gene, found by sequencing. The best outlook of the four, with very low recurrence rates even where the tumour looks high grade. Frequently permits treatment to be de-escalated — radiotherapy or chemotherapy avoided in appropriately selected women. A minority of cases. |
| Mismatch repair deficient | One or more of the mismatch repair proteins is missing, found on immunohistochemistry. Intermediate outlook. Two further consequences: it may indicate Lynch syndrome, with implications for your relatives, and it identifies tumours that respond distinctively to particular classes of systemic treatment. See MMR and MSI testing. |
| p53-abnormal | An abnormal pattern of p53 staining on immunohistochemistry. The least favourable outlook of the four, and generally the group where more intensive treatment is recommended — frequently chemotherapy in addition to radiotherapy. Commoner in serous and clear cell tumours. See clear cell carcinoma. |
| No specific molecular profile | The remaining group, where none of the three defining abnormalities is present. Sometimes called NSMP. Intermediate outlook, and the largest group. Treatment here still leans on the traditional factors — grade, depth of invasion and stage. |
| When more than one is present | An agreed order applies: POLE takes precedence over everything, then mismatch repair deficiency, then p53. So a tumour with both a POLE fault and an abnormal p53 is classified as POLE and treated according to its excellent prognosis rather than its worrying one. |
This is not extra testing you have to request — it is part of current staging. FIGO 2023 incorporates molecular class into how stage is assigned, so a tumour that has not been classified has not been fully staged. If your report does not mention mismatch repair or p53, that is a reasonable question to ask.
Did You Know? The POLE group is the most striking finding in endometrial cancer research of the last decade. These tumours often look alarming under the microscope — high grade, disorganised, all the features a pathologist associates with aggressive behaviour — and they behave remarkably well, with very low rates of recurrence. The explanation is that the fault in POLE causes the tumour to accumulate an enormous number of mutations, which makes it highly visible to the immune system. Before this group was recognised, these women received intensive treatment on the strength of their grade. Now, appropriately selected women can be spared radiotherapy or chemotherapy altogether — which is why the test matters even when everything else about the tumour looks worrying. Sources: The Cancer Genome Atlas Research Network, integrated genomic characterization of endometrial carcinoma; FIGO 2023 staging system for endometrial cancer; ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
What It Actually Changes for You
Five practical consequences, in rough order of how often they matter.
- It can mean less treatment. The point most worth understanding. A POLE-mutated tumour that looks high grade may need no radiotherapy or chemotherapy at all, where grade alone would have prompted both. Without the test, that woman is treated for a risk she does not carry.
- It can mean more treatment. A p53-abnormal tumour that looks low risk on traditional criteria may warrant chemotherapy that would not otherwise have been offered. The classification cuts both ways, which is precisely what makes it useful.
- It identifies Lynch syndrome. Mismatch repair testing is also the screening step for an inherited condition affecting bowel and other cancers, with direct implications for your siblings and children. See Lynch syndrome.
- It shapes options in advanced or recurrent disease. Mismatch repair status determines which classes of systemic treatment are available, and has meaningfully expanded what can be offered. See advanced disease treatment.
- It gives a more honest prognosis. Stage and grade alone gave a blurred picture. Molecular class sharpens it, and for many women the sharper picture is the more reassuring one.
Was Your Tumour Molecularly Classified?
If not, slides can be reviewed and the testing completed. It can change the recommendation in either direction.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
This Can Mean Less Treatment, Not More
A POLE-mutated tumour that looks aggressive frequently is not — and knowing that spares women treatment.
Finding This on Your Own Report
What to look for, and what the wording tends to mean.
Four protein names, present or lost
Your report will list MLH1, PMS2, MSH2 and MSH6. "Retained", "intact" or "preserved" for all four means mismatch repair proficient. "Loss" of any of them means deficient, which places you in that molecular group and prompts further assessment for Lynch syndrome — usually additional testing before any genetic referral, since the commonest cause of MLH1 loss is not inherited at all.
p53 described as wild-type or aberrant
"Wild-type" means the normal pattern and is the reassuring reading, despite sounding technical. "Aberrant", "mutant pattern", "overexpression" or "null pattern" all indicate the p53-abnormal group. It is worth asking directly which of these your report means, since the vocabulary varies between laboratories.
POLE may not have been tested
POLE requires sequencing rather than the staining used for the others, and it is not available everywhere. If your report is silent on it, ask — particularly if your tumour is high grade, because that is exactly the situation where a POLE result could spare you treatment. It can usually be done on the tissue already stored.
A classification stated outright
Many reports now name the group directly. If yours does not but lists the individual results, the group can be worked out from them — and your treating team should be doing that rather than leaving the components unassembled.
Nothing about any of it
Worth a direct question. Since FIGO 2023 incorporates molecular class into staging, a report without it has not fully staged the tumour. Testing can almost always be done later on the stored tissue block. See understanding your pathology report.
Want Your Molecular Result Explained?
Bring your pathology report. What group you are in, and what it should change. The opinion is free.
Questions Worth Asking
Five that get you a concrete answer rather than a general reassurance.
- “Which molecular group is my tumour?” A direct question with a direct answer — one of four names. If the answer is that it has not been determined, that is itself the useful information.
- “Was POLE tested, and if not, would it change anything?” Particularly important with a high-grade tumour, where a POLE result could mean avoiding treatment altogether.
- “How did the molecular result change your recommendation?” This is the question that reveals whether the result was actually used or simply filed. It should have changed something, or there should be a reason it did not.
- “What does my mismatch repair result mean for my family?” If deficient, ask what follow-up testing is planned and whether a genetics referral is indicated. See genetic counselling.
- “Was my case discussed at a tumour board?” Molecular class is exactly the kind of result that benefits from being weighed by surgeons, radiation oncologists and medical oncologists together rather than by one specialty. See the adjuvant decision.
Why Molecular Classification Should Not Be Optional
It is part of staging now — and it is the one test that can reduce the treatment you need as readily as increase it.
MMR / MSI testing as standard
Slides reviewed, not just the summary line
Tumour board for every diagnosis
Lynch counselling built in
Costs explained before you commit
Second opinions welcomed, not resented
Take The Next Step
Ask Which Group You Are In
It has a one-word answer. If nobody can give it, the tumour has not been fully staged.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Molecular Classification — Frequently Asked Questions
What is molecular classification of endometrial cancer?
It is a way of sorting endometrial cancers by what is driving them rather than by how the cells look under a microscope. There are four groups: POLE-ultramutated, mismatch repair deficient, p53-abnormal, and tumours with no specific molecular profile. The first is identified by sequencing the POLE gene; the middle two by immunohistochemistry, a staining technique applied to the tissue already removed. The classification matters because two tumours that look identical down the microscope can behave completely differently, and the molecular group predicts behaviour more reliably than appearance does. It is now incorporated into FIGO 2023 staging, so it forms part of how stage is assigned.
What does POLE-mutated mean, and is it good or bad?
It is the most favourable of the four groups, and this frequently surprises people because POLE-mutated tumours often look aggressive under the microscope. The fault lies in the proofreading function of the POLE gene, so the tumour accumulates an enormous number of mutations — which appears to make it highly visible to the immune system. Recurrence rates are very low. The practical consequence is significant: appropriately selected women with POLE-mutated tumours can safely avoid radiotherapy or chemotherapy that their grade alone would have prompted. If your tumour is high grade and POLE has not been tested, that is worth asking about.
My report says p53 abnormal. What does that mean?
It places your tumour in the group with the least favourable outlook of the four, and it generally means more intensive treatment is recommended — often chemotherapy in addition to radiotherapy. That is difficult to read, and two things are worth holding alongside it. First, it is one factor among several: stage, depth of invasion and whether the disease was completely removed all matter too, and a p53-abnormal tumour caught early and completely excised is a very different situation from one found late. Second, the reason the group is identified is precisely so that treatment can be intensified appropriately, which is the intervention that improves outcomes.
Does everyone get this testing?
They should, and increasingly they do. Mismatch repair testing on all endometrial cancers is now standard practice in most guidelines, both for molecular classification and because it screens for Lynch syndrome. p53 staining is likewise widely done. POLE sequencing is less universally available, because it requires sequencing rather than staining, and it is the component most often missing from a report. Since FIGO 2023 incorporates molecular class into staging, a tumour that has not been classified has not been fully staged. If any of it is absent from your report, ask — the testing can almost always be performed later on the stored tissue block.
If my tumour was not tested, is it too late?
Almost never. The tissue removed at your biopsy or your operation is stored as a preserved block, and immunohistochemistry and POLE sequencing can generally be performed on it long afterwards. This matters most where a decision about treatment after surgery is still open, because the result can change the recommendation in either direction — a POLE result may mean avoiding radiotherapy, a p53 result may mean adding chemotherapy. It is also worth doing where treatment has finished, because mismatch repair status has implications for Lynch syndrome and for your relatives, and for options should the disease ever return.
Medical disclaimer: This page provides general information about molecular classification of endometrial cancer, reviewed by a CION oncologist. It is not a substitute for individual medical advice. Molecular results should be interpreted by your treating team alongside stage, grade, histological type and your clinical circumstances. Decisions about treatment after surgery are individual and are best made following multidisciplinary discussion.